The EPO published Sumitomo Pharma America Inc.'s patent application EP3582815A1 for therapeutic compounds and methods of treating schizophrenia. The application, filed by inventors Hopkins, Koblan, Loebel, and Ogirala, covers compounds under multiple IPC classifications including A61K 31/381, A61K 31/435, A61K 31/55, and various C07D heterocyclic compounds. The A61P 25/18 classification specifically designates central nervous system therapeutic use for schizophrenia treatment.

Pharmaceutical companies developing competing schizophrenia treatments should conduct freedom-to-operate analyses to assess potential patent infringement risks in EPC member states. This patent publication does not impose compliance deadlines or regulatory obligations on third parties. IP legal counsel should monitor the prosecution timeline for potential opposition periods once the patent proceeds to grant.